Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is specifically measuring a blood marker called pTau217 and a memory test called the ISLT on the first day — can you explain what these two measurements are actually looking for, and whether my current test results or symptoms would likely make me a candidate worth discussing with the study team?
2. 2Since this appears to be a screening study designed to identify people who might qualify for future Alzheimer's trials rather than a treatment study itself, can you help me understand what would happen next if my pTau217 levels or ISLT score put me in a certain range — would I automatically be directed toward another Phase 3 trial, and what would that involve?
3. 3pTau217 is a relatively new blood-based biomarker for Alzheimer's — how confident are you in what a high or abnormal result would actually mean for my diagnosis or prognosis, and should I be prepared for results that might be uncertain or hard to interpret?
4. 4Given that this is a Phase 3 level program focused on screening, are there standard diagnostic evaluations or treatments I should consider first before enrolling in a screening study like this, or could participating here actually help clarify my diagnosis faster than the usual path?
5. 5The study involves assessments on Day 1, but could participation in this screening program affect my eligibility for other Alzheimer's treatment studies or standard care options down the road, and is there anything I should watch out for before agreeing to be screened?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.